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The Pidd (p53-induced protein with death domain) gene was shown to be induced by the tumour suppressor p53 and to mediate
p53-dependent apoptosis in mouse and human cells, through interactions with components of both the mitochondrial and the death
receptor signalling pathways. To study the role of Pidd in clinical tumours, we measured its expression by quantitative reverse
transcription-PCR in microdissected oral squamous cell carcinomas (OSCC) with and without p53 mutation. Tumour cell apoptosis
was assessed by in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling. Tumour proliferation was assessed
by immunohistochemical staining for the Ki-67 antigen. We found a wide range of Pidd expression among OSCC. Statistical analysis
revealed an association between Pidd expression and apoptotic index (Mann–Whitney test, Po0.001), consistent with a role of Pidd
in apoptosis in this tumour type. Furthermore, we showed a positive correlation between apoptotic index and proliferative index that
has not been previously described for OSCC. There was no correlation between Pidd expression and the p53 mutation status of
these tumours, suggesting that Pidd expression may be regulated by p53-independent mechanisms. Further characterisation of these
molecular defects in the control of proliferation and apoptosis should help in developing treatments that target OSCC according to
their biological properties.
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Pidd (p53-induced protein with death domain) was characterised
as a p53-induced gene that encodes a death domain containing
protein, and has been shown to mediate p53-dependent apoptosis
in a variety of cell types (Lin et al, 2000). The structural features of
the Pidd protein suggest that it may function as an adaptor protein
that links other apoptotic signalling molecules. Indeed, the Pidd
protein has been shown to form a complex with signalling
molecules in both the death receptor and mitochondrial pathways
(Telliez et al, 2000; Tinel and Tschopp, 2004; Berube et al, 2005).
Currently, little is known about the pathophysiologic role of Pidd
in clinical cancers, and whether Pidd expression may be used as a
marker of apoptotic function that can guide cancer therapy.
Squamous cell carcinoma is the predominant malignant tumour
in the oral cavity. The development of oral squamous cell
carcinoma (OSCC) is strongly associated with smoking and
excessive alcohol consumption, although a minority of OSCC
develops in non-smokers and non-drinkers (Koch and McQuone,
1997). The histopathological appearance of OSCC varies from well-
differentiated tumours with discrete islands of keratinising
carcinoma to poorly differentiated, non-keratinising tumours that
show diffuse invasion by single malignant cells or small groups of
cells (Anneroth et al, 1987). Several molecular abnormalities have
been described for OSCC, particularly mutation of the p53 tumour
suppressor gene (Forastiere et al, 2001; Le and Giaccia, 2003), but
the molecular biology of OSCC of different degrees of differentia-
tion is not well understood.
Abnormalities in the regulation of cell proliferation and
apoptosis play an important role in cancer development (Hanahan
and Weinberg, 2000). In previous studies that examined apoptosis
and their markers in OSCC, the expression of anti-apoptotic
proteins such as Bcl-2 was reported to be strongest in poorly
differentiated carcinoma, whereas pro-apoptotic proteins such as
Bax and high apoptotic index (AI) correlate with well-differ-
entiated carcinoma (Jordan et al, 1996; Xie et al, 1999; Stoll et al,
2000). This would suggest that apoptosis has not been effectively
evaded in well-differentiated, keratinising squamous cell carcino-
mas with low proliferative index (PI) and makes it difficult to
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saccount for the growth of these tumours. Further study of
additional apoptotic markers and pathways are needed to
investigate the relative importance of proliferation and apoptosis
in OSCC. The present study was undertaken to examine the
relationship between expressions of the apoptotic protein Pidd,
tumour cell apoptosis and proliferation.
MATERIALS AND METHODS
Patients and tumour samples
Fifty-five samples of squamous cell carcinoma of the oral cavity
were collected at the time of tumour resection at the University
Health Network, between 1996 and 2000. The protocol for tissue
collection and analysis has been approved by the University Health
Network Research Ethics Board. There were 35 male patients and
20 female patients, aged 25–82, with a median age of 60. There
were five patients under the age of 40. Thirty patients were
smokers, nine were former smokers and 15 had never smoked; the
smoking history of one patient was not available. Thirty-seven
tumours were from the lateral or ventral tongue, 12 from the floor
of mouth, four from buccal mucosa and two were from gingiva/
alveolar mucosa. All samples were previously untreated OSCC.
Tumours were classified at diagnosis according to the TNM
classification (Sobin and Wittekind, 2002) as stage II (17 cases),
stage III (15 cases) and stage IV (23 cases).
Immediately after tumour excision, unfixed tumour samples
were embedded in OCT compound (Tissuetek, Immucor, ON,
Canada), frozen in isopentane prechilled in liquid nitrogen and
stored at  801C until used.
Twelve samples of normal oral mucosa from the buccal mucosa
and gingiva were obtained as surgical waste from patients
undergoing oral surgery. The patients ranged in age from 16 to
39. Unfixed mucosal samples were frozen in OCT compound
following the same procedure as for carcinoma samples. All 12
samples were histologically verified to be free of epithelial
dysplasia and carcinoma, and were used to set a threshold to
separate low Pidd expression from high Pidd expression in the
carcinomas for this study.
Laser capture microdissection and RNA isolation
To assess Pidd expression in OSCC and normal oral epithelium
without the confounding effect of its expression in inflammatory
and stromal cells that are also present within the samples, gene
expression analysis was carried out with RNA prepared from
microdissected cryostat sections. Carcinoma cells and normal
epithelial cells, respectively, were collected from cryostat sections
by laser capture microdissection (PixCell II, Arcturus, Mountain
View, CA, USA), following protocols provided by the manufac-
turer. Approximately 5000 cells were harvested from two to four
sections for each sample. RNA was isolated using a procedure
specially adapted for laser capture microdissection samples
(Stratagene Absolutely RNA Microprep kit, La Jolla, CA, USA).
Following removal of DNA by in-column DNase digestion, the
RNA was eluted in 30ml of elution buffer and stored at  801C until
use.
Quantitative reverse transcription-polymerase chain
reaction analysis of Pidd expression
A 172-bp fragment at the 30 end of the human Pidd mRNA
sequence was amplified in a quantitative real-time, one-step
reverse transcription-polymerase chain reaction (RT-PCR) using
the ABI PRISM 7700 sequence detection system (Perkin-Elmer
Applied Biosystems, Foster City, CA, USA). A 157-bp fragment of
18S RNA was amplified in a parallel reaction using the same RNA
template, to normalise Pidd gene expression values for differences
in the input of RNA template between samples (Wang et al, 2002).
The single-step RT-PCR reaction mix consisted of QuantiTect
SYBR Green RT-PCR 2  Master Mix, 5  Q-solution, QuantiTect
RT Mix (QuantiTect SYBR Green RT-PCR kit, Qiagen Inc.,
Mississauga, ON, Canada), forward and reverse primers at a final
concentration of 0.5mM each, template RNA and nuclease-free
water for a total reaction volume of 50ml. The primers for RT-PCR
of Pidd were: forward 50 CTGGATGAGCAGATCCGTCAC 30,
reverse 50 GGATGCTGTCCTGGTACTTGC 30. Primers for 18S
RNA were: forward 50 GCCTGGATACCGCAGCTAG 30, reverse 50
TTCGCTCTGGTCCGTCTTG 30. The reaction protocol was as
follows: 30min at 501C for reverse transcription, 15min at 951Ct o
inactivate the reverse transcriptase, activate the HotStarTaq DNA
polymerase and denature the DNA, and 40 cycles of 15s at 941C,
30s at 581C and 60s at 721C. Melting curve analysis was performed
after each RT-PCR run to ensure that the fluorescence measure-
ments were based on a single amplified product (ABI PRISM 7700
Sequence Detection System protocol).
Pidd expression was determined relative to the oral carcinoma
cell line UTSCC24A (kindly provided by R Grenman, University of
Turku, Finland), the expression in this cell line being set at 1. In
each run of real time RT-PCR, a dilution series of UTSCC24A RNA
was included with the carcinoma and mucosal RNA samples
and a standard curve of log template vs CT (threshold cycle of
amplification) was generated. The amount of Pidd RNA in the
carcinoma and mucosal RNA samples was obtained by inter-
polation of the standard curve, following the established protocol
(ABI PRISM 7700 Sequence Detection System protocol). Each RNA
sample was measured in duplicate and the average was calculated.
TUNEL assay for apoptosis in tissue sections
Apoptotic cells in cryostat sections of OSCC and normal oral
mucosa were identified by in situ-end labelling of DNA strand
breaks (In situ Cell Death Detection Kit, Roche Applied Science,
Penzberg, Germany), according to the manufacturer’s instructions.
Briefly, cryostat sections were fixed in 4% formaldehyde in PBS
(pH 7.4) for 20min at 15–251C, washed in PBS, incubated with 3%
H2O2 in methanol for 10min at 15–251C to block endogenous
peroxidase activity, rinsed in PBS and permeabilised for 2min with
0.1% Triton X-100 and 0.1% sodium citrate at 41C. The sections
were rinsed and then incubated with terminal deoxynucleotidyl
transferase (TdT) in a buffer that contained fluorescein-tagged
dUTP, for 1h at 371C in a humidified chamber. The sections were
rinsed and next incubated with antifluorescein antibody con-
jugated with horseradish peroxidase, for 30min at 371Ci na
humidified chamber, followed by reaction with the Nova Red
substrate mixture with hydrogen peroxide (Vector Laboratories,
Burlington, ON, Canada). The sections were counterstained with
haematoxylin. Negative controls consisted of sections incubated
with enzyme dilution buffer instead of the TdT enzyme.
Apoptotic cells are identified by dark brownish-red staining
from the terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labelling (TUNEL) reaction over the whole nucleus or
multiple globular bodies in place of the nucleus, together with the
appearance of cell shrinkage. They are typically seen singly and
surrounded by non-apoptotic cells, and can be distinguished from
necrotic cells, which show less intense brown staining, cell swelling
and rupture and form a confluent area within the tissue often with
infiltration of inflammatory cells (Darzynkiewicz et al, 1997;
Garrity et al, 2003; Kroemer et al, 2005).
Immunohistochemical staining for proliferating cells
Staining with the MIB-1 antibody against the Ki-67 antigen was
used to identify cells that were in the G1 through M phases of the
cell cycle (Cattoretti et al, 1992). Immunohistochemical staining
was performed according to previously established procedures
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s(Bradley et al, 2001). Briefly, cryostat sections were placed on
silanised slides and fixed with 3.7% buffered formaldehyde (10min
at room temperature), rinsed in PBS, treated with absolute
methanol (4min at  201C) and then acetone (2min at  201C)
and rinsed again with PBS. Endogenous peroxidase activity was
blocked with 0.3% H2O2 for 10min and nonspecific binding was
blocked by incubation with 10% normal horse serum for 30min.
Sections were incubated with the mouse monoclonal antibody
MIB-1 (Dako Cytomation, Copenhagen; antibody was used at 1–
2mgml
 1 in 0.1% BSA/PBS) for 1h, washed with PBS, incubated
with biotinylated horse anti-mouse IgG (Vector Laboratories,
Burlington, ON, Canada) for 30min, washed again, and incubated
with avidin-biotin horseradish peroxidase complex (Vector
Laboratories) for 30min. The peroxidase label was visualised with
the Nova Red substrate kit (Vector Laboratories). All incubations
were carried out at room temperature. Sections were counter-
stained with haematoxylin. Negative controls were run by omitting
the primary antibody.
Image analysis
The amount of TUNEL staining and MIB-1 staining in the sections
was quantitated with the aid of an image analysis program (Image
ProPlus, version 4.1, Media Cybernetics, MD, USA). For TUNEL
staining, approximately 5000 tumour cells were examined and the
number of apoptotic cells, identified by the criteria given above,
was counted to give the AI, which is the percent of apoptotic cells.
For MIB-1 staining, at least 2000 tumour cells were examined and
the number of MIB-1 positive nuclei was counted to give the PI,
which is the percent of MIB-1 positive cells.
Sequencing of the p53 gene
DNA extraction from tumour samples, amplification of the p53
gene by PCR and direct sequencing of the amplified DNA were
performed according to previously established procedures (Brad-
ley et al, 2001). Briefly, DNA was extracted from cryostat sections
of OSCC after non-malignant tissues have been removed under a
dissecting microscope. The coding section of the p53 gene was
amplified from genomic DNA in three segments that encompassed
exons 2–4, 5–9, and 10 and 11, respectively. DNA sequencing of
the amplified p53 fragments was performed with an automated
sequencer (ABI Prism 377 DNA Sequencer, Applied Biosystems,
Foster City, CA, USA). All mutations were verified with a second
PCR amplification and repeat sequencing.
Statistical analysis
The data were analysed with SPSS v.15 (Statistical Package for
Social Sciences). Differences between groups were examined using
the Mann–Whitney rank-sum test or the Kruskal–Wallis test. A
two-tailed test was used in each analysis. Po0.05 was considered
to be statistically significant.
RESULTS
Pidd expression is associated with apoptosis in OSCC
Our study of OSCC showed a wide range of Pidd expression levels,
from 0.36 to 4.69 relative units, compared with Pidd expression in
normal oral epithelium from individuals with no history of
carcinoma, which varied from 0.56 to 1.20 relative units. To
investigate the functional significance of the variation in Pidd
expression among cases of OSCC, we measured the amount of
apoptosis by in situ TUNEL assay on tumour sections. Terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labelling
was performed on serial sections of the same tumour blocks that
were used for laser capture microdissection, RNA preparation and
real-time RT-PCR, to allow a valid comparison between AI and
Pidd expression. Measurement of Pidd expression and in situ
TUNEL analysis was performed on 43 cases of OSCC.
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labelling staining of normal oral mucosa revealed rare apoptotic
cells within the epithelium (Figure 1A) and also within the
connective tissue, the latter appearing to be apoptotic lympho-
cytes. The amount of apoptosis seen in carcinomas varied
(Figure 1B), with a range of apoptotic indices from 0.03 to
2.25%. The amount of apoptosis that we observed in the TUNEL
assay was generally similar to that reported by others (Xie et al,
1999; Macluskey et al, 2000; Stoll et al, 2000). The late stages of
apoptosis that result in the distinctive morphology of an apoptotic
cell are thought to occur rapidly, followed by phagocytic removal
of the apoptotic bodies by neighbouring cells. Thus, an AI around
1% is interpreted as a significant amount of cell death
(Darzynkiewicz et al, 1997; Lippens et al, 2005).
Figure 2A compares the apoptotic indices of OSCC with low and
high Pidd expression. Low Pidd expression was defined as
expression at or below that found in normal mucosa, which was
1.2 relative units or less. Oral squamous cell carcinomas with low
Pidd expression (16 out of the 43 cases) have significantly lower
apoptotic indices compared to OSCC with high Pidd expression
(Po0.001).
Pidd expression is associated with proliferation in OSCC
We noted that the OSCC samples with high Pidd expression and
high AI were typically non-keratinising carcinomas, whereas OSCC
at the opposite end of the spectrum of Pidd expression showed
large islands with squamous differentiation and central keratinisa-
AB
100 m 100 m
Figure 1 Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling staining of normal oral mucosa (A) and oral squamous carcinoma (B).
Apoptotic cells are stained brownish-red; sections are counterstained with haematoxylin. Bar indicates 100mm.
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stion. Since the non-keratinising histological appearance is usually
associated with a high PI as measured by MIB-1 staining, we
compared the proliferative indices of OSCC with low (1.2 relative
units or less) and high (more than 1.2 relative units) Pidd
expressions (Figure 2B). Oral squamous cell carcinomas with low
Pidd expression have significantly lower proliferative indices
compared to those with high Pidd expression (Po0.001). Figure
3A and B illustrates the association of high AI, high PI and non-
keratinising histological appearance in an OSCC with high Pidd
expression, in contrast with Figure 3C and D, which shows low AI
and low PI in a well-differentiated, keratinising OSCC with low
Pidd expression.
Correlation of Pidd expression with clinical data
We compared Pidd expression and AI in OSCC of smokers or
former smokers, with OSCC in patients who have never smoked.
Of the 43 OSCC for which we measured Pidd expression and AI, 30
were from smokers or former smokers and 12 were from non-
smokers. The smoking history of one patient was not available.
Previous studies have identified differences in molecular pathology
between OSCC in smokers and those in non-smokers. p53
mutation is common in OSCC of smokers, but less often detected
in carcinomas of those who never smoked. Loss of heterozygosity
at selected microsatellite loci is more frequent in OSCC of smokers
than in non-smokers (Koch et al, 1999). However, our data show
no significant correlation between smoking history and either Pidd
expression or AI. For smokers or former smokers, the median Pidd
expression was 1.55 and median AI was 0.44, whereas for non-
smokers median Pidd expression was 1.24 and median AI was 0.38.
We sought to determine if Pidd expression, AI and PI were
related to disease stage at presentation. Of 43 cases of OSCC, 16
patients had stage IV disease, 12 had stage III, 15 had stage II and
none had stage I disease. There was no correlation between stage of
disease and Pidd expression, AI or PI (Table 1). In particular, there
were keratinising OSCC with low Pidd expression, low PI and low
AI that presented as extensive disease at the primary site and
multiple metastases to regional lymph nodes.
Clinical follow-up data were obtained for 36 out of the 43
patients for whom Pidd expression, AI and PI of the carcinoma
were measured. Eighteen patients died of locoregional disease
recurrence and/or distant metastases, after a mean follow-up
period of 13 months (range of 6–31 months). One patient was
found to have recurrent disease at 29 months after surgery and
died of a cerebrovascular accident 5 months later. Fourteen
patients had no evidence of disease after a mean follow-up period
of 84 months (range of 31–118 months). Three patients were lost
to follow-up within 24 months after surgery. For the 32 patients
who were observed for an adequate period (more than 2 years)
after surgical resection, the pattern of disease-free survival was
compared between cases with high Pidd expression and those with
low Pidd expression, and also between cases with high AI and low
AI. There was no statistically significant difference in survival by
Pidd expression or AI (Figure 4A and B).
Pidd expression does not correlate with p53 mutational
status
Pidd mRNA levels were measured by quantitative real-time RT-
PCR in 24 cases of OSCC with known p53 mutation status. There
were 16 cases with p53 mutation, including nine missense
mutations affecting exons 5–8, four mutations to STOP codon
and three frameshift mutations due to single-base pair insertion or
deletion in exons 3–5. Twenty out of the 24 cases have been
previously reported in a study on p53 and p14ARF abnormalities in
OSCC (Bradley et al, 2001). There was no correlation between Pidd
mRNA levels and p53 mutation status. Figure 5 illustrates the
distribution of Pidd expression in OSCC with and without p53
mutation, and in normal oral epithelium from patients with no
history of OSCC. Tumours with p53 mutation showed a wide range
in Pidd expression, with greater than 10-fold difference between
the lowest and highest expression (Table 2).
DISCUSSION
Our finding that Pidd expression in OSCC was associated with
apoptosis represents the first demonstration of a link between Pidd
and apoptosis in clinical tumour samples. Pidd has been
characterised in mouse and human cell lines as a critical
component of apoptotic signalling in response to DNA damage
(Lin et al, 2000; Berube et al, 2005). In vitro studies demonstrated
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Figure 2 (A) Distribution of apoptotic indices in OSCC with low Pidd
expression (N¼16) and OSCC with high Pidd expression (N¼27).
Apoptotic index is measured as the percentage positive cells in an in situ
TUNEL assay. Low Pidd expression is defined as relative Pidd expression of
1.2 or less, high Pidd expression is defined as relative Pidd expression of
more than 1.2 (see Results and Discussion). Each vertical box shows the
median and interquartile range, the bars show the 10th and 90th
percentiles and the dots indicate apoptotic indices outside the 10th and
90th percentiles. There is a significant difference in AI between OSCC with
low Pidd expression and those with high Pidd expression (Mann–Whitney
rank-sum test, Po0.001). (B) Distribution of proliferative indices in OSCC
with low Pidd expression (N¼16) and OSCC with high Pidd expression
(N¼27). Proliferative index is measured as the percentage of cells that are
MIB-1 positive by immunohistochemical staining. Low Pidd expression is
defined as relative Pidd expression of 1.2 or less, high Pidd expression is
defined as relative Pidd expression of more than 1.2. Each vertical box
shows the median and interquartile range, the bars show the 10th and 90th
percentiles and the dots indicate proliferative indices outside the 10th and
90th percentiles. There is a significant difference in PI between OSCC with
low Pidd expression and those with high Pidd expression (Mann–Whitney
rank-sum test, Po0.001).
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sthat exogenous expression of Pidd results in apoptosis and that
Pidd interacts with two other apoptotic signalling proteins, FADD
(Fas-associated death domain protein) and RAIDD (receptor-
interacting protein-associated ICH-1/CED-3 homologous protein
with a death domain). The results of these studies suggest that Pidd
mediates apoptosis through activation of the FADD–caspase 8 and
the RAIDD–caspase 2 complexes, and thus contributes to both the
mitochondrial and death receptor signalling pathways (Tinel and
Tschopp, 2004; Berube et al, 2005). The data shown here suggest
that Pidd may be one of the factors that mediate apoptosis in
OSCC, but further studies are needed to clarify the apoptotic
signalling pathways that are activated in this context.
Tumour growth is the result of disruption of the normal balance
between cell proliferation and cell death. The mechanisms through
which this balance is disrupted determine the characteristics and
evolution of the tumour (Sanchez-Beato et al, 2003). Our study of
Pidd expression and apoptosis has revealed a subset of OSCC with
a well-differentiated histological appearance that is associated with
low Pidd expression, low AI and low PI. These tumours may be
analogous to the ‘low-growth fraction B-cell lymphomas’ that
include follicular lymphoma and B-cell chronic lymphocytic
leukaemia, which are distinguished by resistance to apoptosis. In
these malignancies, tumour growth is predominantly the result of
abnormal cell survival since the PI is low (Sanchez-Beato et al,
2003). Tumour cells can acquire resistance to apoptosis by various
mechanisms that interfere at different levels of apoptosis signalling
and involve both the death receptor and mitochondrial pathways
(Igney and Krammer, 2002). Previous studies of apoptosis in OSCC
have described a correlation between high AI and well-differ-
entiated carcinomas (Xie et al, 1999) and between the antiapopto-
tic protein Bcl-2 and high histological grade (less differentiated
carcinomas) (Jordan et al, 1996; Stoll et al, 2000). Our data indicate
the opposite relationship of low AI in well-differentiated tumours,
and provide an explanation for tumour cell accumulation in well-
differentiated carcinomas that have a low proliferation rate.
Further studies of the apoptotic pathway that is mediated by Pidd
AC
B D
Figure 3 (A and B) In situ TUNEL for apoptotic cells (A) and MIB-1 staining for proliferating cells (B) in an OSCC with Pidd overexpression compared to
normal oral epithelium (Pidd expression¼4.09 relative units, AI¼1.31%, PI¼42%). (C and D) In situ TUNEL for apoptotic cells (C) and MIB-1 staining for
proliferating cells (D) in an OSCC with Pidd underexpression compared to normal oral epithelium (Pidd expression¼0.36 relative units, AI¼0.03%,
PI¼19%). Apoptotic cells (A and C) and MIB-1 expressing cells (B and D) are stained brownish-red and the sections are counterstained with haematoxylin.
Bar indicates 100mm.
Table 1 Pidd expression, apoptotic index and proliferative index in OSCC according to disease stage (UICC staging system, 2002)
Stage II OSCC (N¼15) Stage III OSCC (N¼12) Stage IV OSCC (N¼16)
Median
(7standard
deviation)
25th–75th
Quartiles
Median
(7standard
deviation)
25th–75th
Quartiles
Median
(7standard
deviation)
25th–75th
Quartiles
Pidd expression 1.33 (70.46) 1.01–1.62 1.58 (71.08) 0.82–1.98 1.69 (71.18) 0.91–1.92
Apoptotic index 0.38 (70.24) 0.22–0.49 0.52 (70.57) 0.20–0.76 0.43 (70.34) 0.18–0.66
Proliferative index 25 (78.70) 15–30 24 (77.72) 18–30 31 (712.43) 14–38
OSCC¼oral squamous cell carcinoma. There are no significant differences among OSCC of different disease stages in Pidd expression, apoptotic index or proliferative index
(Kruskal–Wallis test for Pidd expression, apoptotic index and proliferative index: P¼0.465, P¼0.404 and P¼0.459, respectively).
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sshould increase our understanding of the apoptotic defect that we
observed in well-differentiated OSCC. Restoration of this apoptotic
pathway may provide a selective approach to eradicate this subset
of OSCC (Reed, 2006).
Our study has revealed another subset of OSCC that is
characterised by a non-keratinising histological appearance, high
Pidd expression, high AI and high PI. Studies of tumour cell lines
and mouse tumour models have shown that oncogene activation
and aberrant proliferation can trigger apoptosis through coupling
of proliferative signalling pathways with apoptotic pathways (Igney
and Krammer, 2002; Lowe et al, 2004). Abnormal proliferation
may also trigger apoptosis in tumour cells because of hypoxia,
nutrient deprivation, detachment from the extracellular matrix and
adjacent cells, telomere shortening or other forms of DNA damage
(Jaattela, 2004). Inactivation of apoptosis is thought to be required
for tumour initiation and progression (Igney and Krammer, 2002;
Jaattela, 2004; Lowe et al, 2004). However, studies of clinical
tumour samples indicate that apoptosis may not be completely
inactivated even in established malignancies. High-grade lympho-
mas such as lymphoblastic lymphoma and Burkitt’s lymphoma are
characterised by high PI and high AI. A positive correlation
between PI and AI has been demonstrated for some types of
malignant tumours (Kiberu et al, 1996; Zhang and Takenaka, 2000;
Bai et al, 2003). These findings suggest that rapidly proliferating
tumour cells may tolerate continuing apoptosis, when there is a
high proliferation rate to allow net tumour expansion despite cell
loss from apoptosis. Our data indicate that increased expression of
Pidd may serve as a marker of activated apoptosis in a subset of
OSCC.
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Figure 4 (A and B) Kaplan–Meier plot for disease-free survival by Pidd expression (A) and by AI (B) for 32 cases of OSCC. Low Pidd expression is
defined as relative expression of 1.2 or less, high Pidd expression is defined as relative expression of more than 1.2. Low AI is defined as AI that is at or below
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P
i
d
d
 
e
x
p
r
e
s
s
i
o
n
 
(
r
e
l
a
t
i
v
e
 
u
n
i
t
s
)
 
5
4
3
2
1
0
p53 mutation No p53 mutation
Carcinoma Normal epithelium
No p53 mutation
Figure 5 Distribution of Pidd expression in OSCC with p53 mutation
(N¼16), OSCC with no detected p53 mutation (N¼8) and normal oral
mucosa (N¼12). Each vertical box shows the median and interquartile
range, the bars show the 10th and 90th percentiles and the dots indicate
Pidd expression values outside the 10th and 90th percentiles. There is no
significant difference in Pidd expression between OSCC with p53 mutation
and OSCC with no p53 mutation (Mann–Whitney rank-sum test,
P¼0.426).
Table 2 p53 mutation status and Pidd expression in oral squamous cell
carcinomas
Sample p53 mutation status
a Pidd expression
b
1 Exon 5 Arg175His
c 0.36
2 Exon 5 Val172Asp 0.49
3 Exon 4 Trp91Stop 0.58
4 Exon 5 Tyr163His 0.60
5 Exon 3 32ins1bp 0.64
6 Exon 6 Glu204Stop 0.67
7 Exon 6 Glu204Stop 0.68
8 Exon 8 Glu285Val 0.72
9 Exon 8 Pro278Leu 0.96
10 Exon 7 Tyr236Stop 0.88
11 Exon 5 Ser127Phe 0.92
12 Exon 6 Tyr220Cys 1.10
13 Exon 6 Tyr220Cys 1.22
14 Exon 4 88del1bp 1.71
15 Exon 8 Arg280Ser 1.92
16 Exon 5 161del1bp 4.69
17 No mutation detected 0.60
18 No mutation detected 0.79
19 No mutation detected 0.81
20 No mutation detected 0.83
21 No mutation detected 0.97
22 No mutation detected 0.97
23 No mutation detected 1.49
24 No mutation detected 2.59
aDetermined by direct sequencing of the p53 gene from tumour samples.
bPidd
mRNA levels were measured by real-time RT-PCR and normalised to the expression
of 18S RNA. The normalised expression is given in relative units, where the
expression in the oral squamous carcinoma cell line UT-SCC24A is set at 1.
cThe
number refers to the affected codon.
Pidd expression correlates with apoptosis in oral carcinoma
G Bradley et al
1430
British Journal of Cancer (2007) 96(9), 1425–1432 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sIn this study, Pidd expression was measured by quantitative RT-
PCR in microdissected samples. This provided a sensitive and
specific measurement of Pidd expression, but did not allow Pidd
expression to be studied at the single-cell level. We performed
immunohistochemical staining of selected cases of OSCC using an
antiserum against Pidd (Berube et al, 2005) but were not able to
demonstrate specific staining for Pidd. In situ hybridisation of
tumour sections for Pidd mRNA was also unsuccessful, probably
due to the low level of expression within individual cells.
We did not observe a significant difference in disease-free
survival of patients with low or high Pidd expression in their
carcinoma. Likewise, no difference in disease-free survival could
be demonstrated for patients with OSCC of low or high AI. These
findings suggest that Pidd expression and AI by TUNEL assay
cannot predict the outcome of treatment in patients with OSCC
who have been treated with surgical resection as the primary
approach. Apoptotic cell death may be a more significant factor in
determining tumour cell death and success of cancer treatment
when radiation and/or cytotoxic drugs are used as primary therapy
(Homma et al, 1999). Further study of patients with OSCC who are
treated with primarily with radiation and/or chemotherapy would
be helpful to determine whether Pidd expression and AI can serve
as biological markers to indicate responsiveness to treatment.
Pidd was first described as a p53 target gene whose expression
may be directly induced by p53. An association between Pidd
expression and p53 status was demonstrated in different cell types
(Lin et al, 2000). Surprisingly, our data did not reveal a correlation
between Pidd mRNA levels and p53 mutation status. In particular,
there were tumours with p53 mutation that showed high Pidd
expression. The lack of correlation between p53 status and Pidd
expression in OSCC suggests that Pidd is regulated by factors other
than p53 in this tumour type. The expression of two other p53
target genes, p21 and Bax, have been examined in head and neck
cancer samples in relation to their p53 status. There was no
correlation between p53 status and the expression of p21 or Bax
(Lavieille et al, 1998; Hotz et al, 1999; Osman et al, 2002; Xie et al,
2002). These findings suggest that, whereas the p53 tumour
suppressor can induce numerous genes involved in growth arrest
and apoptosis, these genes are also regulated by p53-independent
mechanisms in a network of signalling pathways. This argues
against a linear model of p53 function in which the level of
expression of a p53 target gene such as p21, Bax or Pidd can be
used to indicate p53 transcriptional activity.
CONCLUSION
The expression of Pidd correlates with apoptosis in OSCC. Analysis
of Pidd expression led to identification of subsets of OSCC that are
distinguished by differences in differentiation, AI and PI.
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